ESAs were recommended as a treatment option in CIA when the Hb level approached or fell below 10 g/dL, and in less severe anemia (Hb > 10 g/dL and < 12 g/dL), with use determined by clinical circumstances. The gene discussed is GSTM1; the disease is anemia (phenotype).